Ascenta Capital
Venture capitalWilmington
Also known as ASCENTA CAPITAL MANAGEMENT CO., L.P.
Fund manager profile
Ascenta Capital is a venture fund manager based in Wilmington. SEC filings show 1 venture fund on record, most recently Ascenta Capital Fund I, L.P. ($350M offering) filed February 2025.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
What they invest in
from 8 of 9 portfolio companiesBiotech ×8Deep Tech ×2Digital Health ×2Healthtech ×2Medical Devices ×2AI & Machine Learning ×1Crypto & Web3 ×1
HQs:United States×7Canada×1
Investments · 9 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 12023 · 35 dated
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inNeil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)inMichael Secora(Chief Financial Officer and Chief Corporate Development Officer)in
Co-investorsAbingworthCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue ManagementEisai Innovation, Inc.+4 more
TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.
BiotechDeep TechHealthtechLexington, US
Patrick Trojer(President & CEO, Co-founder)
Co-investorsAtlas VentureBessemer Venture PartnersLightspeed Venture PartnersPfizer VenturesRA CapitalPfizer Venture Investments
San Diego, US
Board seatLorence Kim· per SEC Form D · $200M raise · filed Aug 2023
Co-investorsLAVLilly Asia VenturesSilverArc PrivateTCG Crossover
Faction is a venture capital firm that invests in cryptocurrency and blockchain projects at the seed and series A stages, focusing on entrepreneurs building fundamental utility across the technology stack.
BiotechCrypto & Web3New York, US
Oren Harnevo(Executive Officer, Director)Ronald Bianchini, Jr.(Executive Officer, Director)Roneil Rumburg(Cofounder)Christina Calvaneso(Executive Officer)Brian Pozesky(Executive Officer)Jeff Fagel(Executive Officer)
Board seatLorence Kim· per SEC Form D · filed Dec 2023
Co-investorsAccelAdaverseAlephAxeleo CapitalBluebird VenturesBright Pixel Capital+36 more
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.
BiotechMedical DevicesCambridge, US
Gary D Glick(Executive Officer, Director)
BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)
Board seatLorence Kim· per SEC Form D · $121.1M raise · filed Aug 2024
Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess FundGreatPoint Ventures+6 more
BiotechWaltham, US
Joshua Resnick(Director)Milind Deshpande(Executive Officer, Director)Simon Read(Director)
BoardDavid Grayzel(Director)
Board seatLorence Kim· per SEC Form D · $120.1M raise · filed Dec 2025
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
Co-investorsAndreessen HorowitzDelos CapitalGeneral CatalystLightspeed Venture PartnersLongitude CapitalLumira Ventures+8 more
BiotechMenlo Park, US
Mani Subramanian(Executive Officer, Director)Gangadhara Ganapati(Executive Officer, Director)
BoardMatthew Young(Director)inSrinivas Akkaraju(Director)Cory Freedland(Director)Edward Fleming(Director)
Co-investorsLongitude CapitalSamsara BioCapital
Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.
BiotechDigital HealthHealthtech
Vishal Patelin
Co-investorsAtlas VentureBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedFidelity Investments+3 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Portfolio news
latest coverage across their companies
Triveni · fiercebiotech.com · Aug 12, 2026
Odyssey Therapeutics · finance.yahoo.com · Aug 11, 2026
Nominal · medicalbuyer.co.in · Jul 14, 2026
Iambic · geekwire.com · Jul 13, 2026
Frequently asked questions
- Where is Ascenta Capital located?
- Ascenta Capital is headquartered in Wilmington, US.